Abstract
Major depressive disorder affects millions of people and leads to debilitating symptoms. Although conventional antidepressants have been available and are often beneficial, they have several limitations, including a slow onset of action and an inadequate response for a substantial fraction of patients. Recently, ketamine—primarily a noncompetitive NMDA receptor antagonist, among other actions—was approved as a novel treatment for treatment-resistant depression and suicidal ideation. This was an exciting development because ketamine can relieve depressive symptoms rapidly and with sustained effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have